Bank of America
RAPP

Bank of America’s Rapport Therapeutics RAPP Stock Holding History

Bank of America’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.47M Buy
110,826
+76,273
+221% +$2.15M ﹤0.01% 3736
2025
Q4 		$1.05M Sell
34,553
-23,508
-40% -$651K ﹤0.01% 4497
2025
Q3 		$1.72M Buy
58,061
+45,934
+379% +$819K ﹤0.01% 4943
2025
Q2 		$138K Buy
12,127
+4,666
+63% +$49.5K ﹤0.01% 6353
2025
Q1 		$74.8K Buy
7,461
+883
+13% +$11.5K ﹤0.01% 6620
2024
Q4 		$117K Sell
6,578
-12,532
-66% -$278K ﹤0.01% 6331
2024
Q3 		$391K Buy
+19,110
New +$411K ﹤0.01% 5645

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Bank of America's RAPP Position: Q1 2026 in Review

Bank of America increased its Rapport Therapeutics (RAPP) stake by 221% in Q1 2026, buying an estimated $2.15M and bringing the position to 110,826 shares worth $3.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3736.

Bank of America first reported a position in RAPP in Q3 2024 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Bank of America held 110,826 shares of Rapport Therapeutics worth $3.47M as of Q1 2026.
  • Bank of America bought 76,273 Rapport Therapeutics shares in Q1 2026, an estimated $2.15M.
  • Rapport Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3736 holding.
  • Bank of America first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.